TY - JOUR
T1 - A Novel Clinical Scoring System for Perioperative Morbidity in Metastatic Spinal Tumor Surgery
AU - Ramos, Rafael Dela Garza
AU - Benton, Joshua A.
AU - Gelfand, Yaroslav
AU - Echt, Murray
AU - Hamad, Mousa K.
AU - Kinon, Merritt D.
AU - Yanamadala, Vijay
AU - Yassari, Reza
N1 - Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Study Design. Retrospective cohort study. Objective. To evaluate a scoring system to predict morbidity for patients undergoing metastatic spinal tumor surgery (MSTS). Summary of Background Data. Multiple scoring systems exist to predict survival for patients with spinal metastasis. The potential benefits and risks of surgery need to be evaluated for patients with disseminated cancer and limited life expectancy. Few scoring systems exist to predict perioperative morbidity after MSTS. Methods. We reviewed records of patients who underwent MSTS at our institution between 2013 and 2019. All perioperative complications occurring within 30 days were recorded. A clinical scoring system consisting of five variables (age > 70 yr, hypoalbuminemia, poor preoperative functional status [Karnofsky 40], Frankel Grade A-C, and multilevel disease >2 continuous vertebral bodies) was evaluated as a predictive tool for morbidity; every parameter was assigned a value of 0 if absent or 1 if present (total possible score = 5). The effect of the scoring system on morbidity was evaluated using stepwise multiple logistic regression. Model accuracy was calculated by receiver operating characteristic analysis. Results. One hundred and five patients were identified, with a male prevalence of 58.1% and average age at surgery of 61 years. The overall 30-day complication rate was 36.2%. The perioperative morbidity was 4.6%, 30.0%, 53.9%, and 64.7% for patients with scores of 0, 1, 2, and >3 points, respectively (P<0.001). On multiple logistic regression analysis controlling for covariates not present in the model, the scoring system was significantly associated with 30-day morbidity (OR 3.11; 95% CI, 1.72-5.59; P<0.001). The model's accuracy was estimated at 0.75. Conclusion. Our proposed model was found to accurately predict perioperative morbidity after MSTS. The Spine Oncology Morbidity Assessment (SOMA) score may prove useful for risk stratification and possibly decision-making, though further validation is needed.
AB - Study Design. Retrospective cohort study. Objective. To evaluate a scoring system to predict morbidity for patients undergoing metastatic spinal tumor surgery (MSTS). Summary of Background Data. Multiple scoring systems exist to predict survival for patients with spinal metastasis. The potential benefits and risks of surgery need to be evaluated for patients with disseminated cancer and limited life expectancy. Few scoring systems exist to predict perioperative morbidity after MSTS. Methods. We reviewed records of patients who underwent MSTS at our institution between 2013 and 2019. All perioperative complications occurring within 30 days were recorded. A clinical scoring system consisting of five variables (age > 70 yr, hypoalbuminemia, poor preoperative functional status [Karnofsky 40], Frankel Grade A-C, and multilevel disease >2 continuous vertebral bodies) was evaluated as a predictive tool for morbidity; every parameter was assigned a value of 0 if absent or 1 if present (total possible score = 5). The effect of the scoring system on morbidity was evaluated using stepwise multiple logistic regression. Model accuracy was calculated by receiver operating characteristic analysis. Results. One hundred and five patients were identified, with a male prevalence of 58.1% and average age at surgery of 61 years. The overall 30-day complication rate was 36.2%. The perioperative morbidity was 4.6%, 30.0%, 53.9%, and 64.7% for patients with scores of 0, 1, 2, and >3 points, respectively (P<0.001). On multiple logistic regression analysis controlling for covariates not present in the model, the scoring system was significantly associated with 30-day morbidity (OR 3.11; 95% CI, 1.72-5.59; P<0.001). The model's accuracy was estimated at 0.75. Conclusion. Our proposed model was found to accurately predict perioperative morbidity after MSTS. The Spine Oncology Morbidity Assessment (SOMA) score may prove useful for risk stratification and possibly decision-making, though further validation is needed.
KW - Metastases
KW - morbidity
KW - predictor
KW - scoring system
KW - spine surgery
UR - http://www.scopus.com/inward/record.url?scp=85099429034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099429034&partnerID=8YFLogxK
U2 - 10.1097/BRS.0000000000003733
DO - 10.1097/BRS.0000000000003733
M3 - Article
C2 - 33038202
AN - SCOPUS:85099429034
SN - 0362-2436
VL - 46
SP - E161-E166
JO - Spine
JF - Spine
IS - 3
ER -